Cargando…

Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients

The most commonly used regimens fail to eradicate Helicobacter pylori (H. pylori) infection in 5–10% of patients. Those not cured with treatments based on amoxicillin, clarithromycin, nitroimidazoles, fluoroquinolones, bismuth or tetracycline have no other conventional options thereafter. In this pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ribaldone, Davide Giuseppe, Fagoonee, Sharmila, Astegiano, Marco, Durazzo, Marilena, Morgando, Anna, Sprujevnik, Tatiana, Giordanino, Chiara, Baronio, Monica, De Angelis, Claudio, Saracco, Giorgio Maria, Pellicano, Rinaldo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406425/ https://www.ncbi.nlm.nih.gov/pubmed/30736338 http://dx.doi.org/10.3390/jcm8020199

Ejemplares similares

Helicobacter pylori and Respiratory Diseases: 2021 Update
por: Durazzo, Marilena, et al.
Publicado: (2021)

Amoxycillin and Metronidazole Therapy for Helicobacter pylori Eradication: A 10-Year Trend in Turin, Italy
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2017)

2013 Update on Celiac Disease and Eosinophilic Esophagitis
por: Pellicano, Rinaldo, et al.
Publicado: (2013)

Helicobacter pylori eradication: the relevance of a periodic update
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Response to: Comment on “Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2016)

Strategies for Helicobacter pylori eradication in the year 2020
por: Pellicano, Rinaldo, et al.
Publicado: (2020)

A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Response to: Reply on “Renewed Helicobacter pylori Management and Therapy in 2015”
por: Fagoonee, Sharmila, et al.
Publicado: (2016)

Comment on Helicobacter pylori seroprevalence and the occurrence and severity of psoriasis
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2017)

One or Two Weeks of Treatment with Helicobacter pylori “Standard” Triple Therapy in the Year 2015?
por: Pellicano, Rinaldo, et al.
Publicado: (2015)

Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis
por: Carli, Edoardo, et al.
Publicado: (2020)

Comments regarding use of rifabutin for Helicobacter pylori eradication
por: Graham, David Y.
Publicado: (2021)

Trends in the Comprehension and Management of Gastrointestinal Tract Disorders
por: Durazzo, Marilena, et al.
Publicado: (2022)

Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity (“lymphocytic enterocolitis”)?
por: Bonagura, Gabriele Antonio, et al.
Publicado: (2016)

Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties
por: Borraccino, Antonia Valeria, et al.
Publicado: (2022)

Comment #2 on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2018)

Extra-Intestinal Manifestations of Celiac Disease: What Should We Know in 2022?
por: Durazzo, Marilena, et al.
Publicado: (2022)

Autoimmune Hepatitis and Fibrosis
por: Pellicano, Rinaldo, et al.
Publicado: (2023)

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
por: Bertani, Lorenzo, et al.
Publicado: (2020)

Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of Helicobacter pylori: Randomized ERADICATE Hp Trial
por: Kalfus, Ira N., et al.
Publicado: (2020)

History of Inflammatory Bowel Diseases
por: Actis, Giovanni Clemente, et al.
Publicado: (2019)

Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection
por: Navarro-Jarabo, José M, et al.
Publicado: (2007)

Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2020)

Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains
por: Kuo, Chia-Jung, et al.
Publicado: (2020)

The Evolving Incidence of Hepatitis C Virus Infection in Italy
por: Pellicano, Rinaldo, et al.
Publicado: (2012)

Promises of Fibroblast Growth Factor Receptor–Directed Therapy in Tailored Cancer Treatment
por: Fagoonee, Sharmila, et al.
Publicado: (2020)

Does the Microbiota Play a Pivotal Role in the Pathogenesis of Irritable Bowel Syndrome?
por: Fagoonee, Sharmila, et al.
Publicado: (2019)

Rifabutin for the Treatment of Helicobacter pylori Infection: A Review
por: Gisbert, Javier P.
Publicado: (2020)

Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Rifabutin-based High-dose Proton-pump Inhibitor and Amoxicillin Triple Regimen as the Rescue treatment for Helicobacter pylori
por: Lim, Hyun Chul, et al.
Publicado: (2014)

Finally, it is Bismuth's Time
por: Ribaldone, Davide G., et al.
Publicado: (2017)

On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Comment on “Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2017)

The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
por: Vernero, Marta, et al.
Publicado: (2020)

Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)
por: Nyssen, Olga P., et al.
Publicado: (2022)

Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐line Helicobacter pylori eradication regimen
por: Inokuchi, Kazumi, et al.
Publicado: (2022)

Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis
por: Liu, Xiaoqun, et al.
Publicado: (2015)

Screening and surveillance of oesophageal varices in patients with HCV‐positive liver cirrhosis successfully treated by direct‐acting antiviral agents
por: Ciancio, Alessia, et al.
Publicado: (2022)

Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori
por: Yun, Sang-Pil, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_dov4429ih9m6121ikpd7dgrncq